



Prescription Drug Affordability Board Party Pros / Cons & Concerns

A **Prescription Drug Affordability Board** is a state group that reviews and may cap drug prices. It can limit access to essential, high-cost therapies and risk reducing treatment options for patients.

Party	Pro (Arguments Supporting PDAB Policies)	Cons/Concerns (Arguments Raising Caution for Rare Disease Patients)
Democrats	<ul style="list-style-type: none"> • PDABs aim to address high drug prices and improve affordability for patients overall. • Provide states with tools to review costly medications and recommend strategies to control spending. • Supporters see PDABs as a way to increase transparency and reduce financial burdens on families. 	<ul style="list-style-type: none"> • Concern from within the party that applying cost caps to rare disease therapies could reduce access to lifesaving treatments. • Worries that price limits may lead manufacturers to withdraw small-market rare disease drugs from certain states. • Equity concerns if rare disease patients lose access while larger population drugs are prioritized.
Republicans	<ul style="list-style-type: none"> • Support PDABs when framed as state-led initiatives that bring transparency to drug pricing and protect taxpayers from escalating costs. • Viewed by some as a way to encourage market discipline and reduce state healthcare spending. • Appeals to constituents frustrated by high prescription costs. 	<ul style="list-style-type: none"> • Strong concerns about government price-setting and its impact on innovation, especially for rare disease treatments requiring sustained R&D investment. • Fear that price caps could reduce availability of specialized therapies or limit provider choice. • Skepticism about creating new state bureaucracies with authority over high-cost, low-volume therapies.